Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study
Table 3
Received therapy combinations and adverse drug reactions to those therapies.
Therapy combinations
Patients
Patients who had an ADR (relative frequency)
Intravenous mistletoe therapy alone
445
19 (4.3)
Intravenous mistletoe therapy
+
chemotherapy*
187
3 (1.6)
chemotherapy* + immunotherapy
17
0
surgery
13
0
bisphosphonates
12
0
chemotherapy* + radiation therapy
12
0
immunotherapy
9
0
hormone therapy
5
0
radiation therapy
3
0
bisphosphonates + hormone therapy
2
0
signal transduction inhibitors
2
0
chemotherapy* + hormone therapy + signal transduction inhibitors
1
0
chemotherapy* + signal transduction inhibitors
1
0
A total of 201 patients (55% of all patients that had chemotherapy and 42% of all i.v. mistletoe patients) received i.v. mistletoe and chemotherapy within close temporal proximity (very often on the same day). Of these patients, 63% also received corticosteroids as prechemotherapy medication (i.e., dexamethasone or prednisolone) at least once.